Five Off-road Mobility Devices to Get You Outside in Winter
By Codi Darnell November 15, 2022 It may feel like fall just arrived, but we are one month away from winter. Yes, winter is coming
We create innovative solutions for the treatment of nervous system damage due to trauma or disease.
NervGen is a publicly traded (TSX-V: NGEN, OTCQX: NGENF) clinical stage biotech company dedicated to developing novel drugs for the treatment of spinal cord injury, multiple sclerosis and Alzheimer’s disease.
Sign up to our newsletter
In this inspiring and heartfelt video, Dr. Jerry Silver, Professor of Neurosciences, Case Western Reserve University, shares his journey and how the research carried out in his lab led to the formation of NervGen.
The video highlights how NervGen is developing Dr. Silver’s foundational discoveries into a disruptive technology that is aimed at changing the paradigm of how nervous system damage will be treated.
Media
By Codi Darnell November 15, 2022 It may feel like fall just arrived, but we are one month away from winter. Yes, winter is coming
News Release
Seasoned pharmaceutical executive with extensive experience in high-growth life sciences companies joins NervGen Leadership appointment supports the company’s mission to advance NVG-291 after the completion
Article
NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial. The company’s lead target indication is spinal cord injury.
Contact
112-970 Burrard Street
Unit 1290
Vancouver, BC V6Z 2R4
Phone: (778) 731-1711
Email: info@nervgen.com
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |